Abstract
Numerous substances are available for the treatment of metastatic renal cell carcinoma (mRCC). Therefore, medical treatment of patients with mRCC has become a very complex subject. This review summarises clinical studies and typical side-effects of currently available agents that have been approved in Germany. The authors give suggestions for the use of these substances in the different therapy lines.
Translated title of the contribution | Current recommendations for the systemic treatment of metastatic renal cell carcinoma |
---|---|
Original language | German |
Journal | Aktuelle Urologie |
Volume | 50 |
Issue number | 6 |
Pages (from-to) | 606-611 |
Number of pages | 6 |
ISSN | 0001-7868 |
DOIs | |
Publication status | Published - 04.09.2019 |
Research Areas and Centers
- Research Area: Luebeck Integrated Oncology Network (LION)